LONDON: Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that it has submitted a patent application in respect of the Company’s bispecific designs for antigen display.
The Company uses antigens to generate and screen for specific antibodies during the Antibody Discovery process. Fusion’s new designs for antigens consist of two parts; the antigen part and a “reporter” part, referred to as a “bispecific”.
The Company believes that the use of a reporter part, which can be any number of useful tags for various antibody screening assays, will increase the success rate in identifying highly potent antibodies from Fusion’s range of Antibody Discovery technologies.
Simon Douglas, Chairman of Fusion Antibodies, commented: “Our dedicated team of scientists continues to work on next generation antibody discovery, and we see significant opportunities in this field. We look forward to contributing to the growing body of research concerning the scope of antibody production and design, while also growing our patent portfolio.”